Description: AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. It offers Atlas antibodies; essential antibodies for bio-researchers; and Absignal, a western detection agent. The company's products in pipeline include NEST platform technology products for stomach, breast, colorectal, lung, and solid cancers; AffiMab platform technology products for pancreatic, colorectal, and lung cancers, as well as for rheumatoid arthritis and psoriasis; and CAR-T platform technology products for hematologic cancers. It also develops BioSynergy antibody drugs that act as a mechanism for the existing disease protein based on YPLUS and AffiMab. In addition, the company offers peptide and protein for antibody development; monoclonal antibody service for various antigens comprising peptide, protein, and recombinant proteins; polyclonal antibody for use in research; ELISA, a method for drug development, diagnostic kit, HCP kit, and protein kit at various industry and academia; and antibody drug development services. It sells its products through distributors in Japan, China and Hong Kong, Taiwan, Singapore, and Malaysia. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.
Home Page: www.abclon.com
No 1401, Ace Twin Tower 285
Seoul,
08381
South Korea
Phone:
82 2 2109 1294
Officers
| Name | Title |
|---|---|
| Kim Kyu-Tae | Chief Scientific Officer and Member of Scientific Advisory Board |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 48.6232 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |